Vaginal Cancer

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Vaginal Cancer

MalaCards integrated aliases for Vaginal Cancer:

Name: Vaginal Cancer 12 52 42 15
Malignant Neoplasm of Vagina 12 32
Vaginal Neoplasms 43 71
Vaginal Malignant Epithelial Tumor 58
Malignant Vaginal Neoplasm 71
Malignant Tumor of Vagina 12
Malignant Vaginal Tumor 12
Neoplasm of Vagina 12
Vaginal Carcinoma 58
Vaginal Neoplasia 71
Vaginal Neoplasm 17
Vagina Carcinoma 71
Vagina Neoplasm 12
Vaginal Tumor 12


Orphanet: 58  
Rare gynaecological and obstetric diseases

External Ids:

Disease Ontology 12 DOID:119
ICD9CM 34 184.0
MeSH 43 D014625
NCIt 49 C3437 C7410
ICD10 32 C52
ICD10 via Orphanet 33 C52
UMLS via Orphanet 72 C0262659
Orphanet 58 ORPHA180247
UMLS 71 C0042237 C0042258 C0262659 more

Summaries for Vaginal Cancer

MedlinePlus : 42 Vaginal cancer is a rare type of cancer. It is more common in women 60 and older. You are also more likely to get it if you have had a human papillomavirus (HPV) infection or if your mother took diethylstilbestrol (DES) when she was pregnant. Doctors prescribed DES in the 1950's to prevent miscarriages. You are also at higher risk if you have had abnormal cells in the vagina, cervix, or uterus. It often doesn't have early symptoms. However, see your doctor if you notice Bleeding that is not your period A vaginal lump Pelvic pain A Pap test can find abnormal cells that may be cancer. Vaginal cancer can often be cured in its early stages. Treatment might include surgery, radiation therapy, and chemotherapy. NIH: National Cancer Institute

MalaCards based summary : Vaginal Cancer, also known as malignant neoplasm of vagina, is related to vaginal disease and vagina sarcoma, and has symptoms including pelvic pain and vaginal pruritus. An important gene associated with Vaginal Cancer is HLA-G (Major Histocompatibility Complex, Class I, G), and among its related pathways/superpathways is Viral carcinogenesis. The drugs Ondansetron and Granisetron have been mentioned in the context of this disorder. Affiliated tissues include vagina, breast and cervix, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

Disease Ontology : 12 A female reproductive system cancer that is located in the vagina.

Wikipedia : 74 Vaginal cancer is a malignant tumor that forms in the tissues of the vagina. Primary tumors are most... more...

Related Diseases for Vaginal Cancer

Diseases related to Vaginal Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 335)
# Related Disease Score Top Affiliating Genes
1 vaginal disease 32.7 TP53 LINC01191 GP5
2 vagina sarcoma 31.3 PGR ESR1 CALD1
3 vulvar intraepithelial neoplasia 30.7 TP53 CDKN2A
4 keratinizing squamous cell carcinoma 30.0 TP53 LINC01191 KRT7 CDKN2A
5 suppressor of tumorigenicity 3 30.0 UBE3A TP53 CDKN2A
6 penile cancer 29.9 TP53 GP5 CDKN2A
7 vulva cancer 29.9 TP53 LINC01191 KRT7 GP5 CDKN2A
8 adenocarcinoma in situ 29.7 KRT7 INSM1 CDKN2A
9 cervix uteri carcinoma in situ 29.6 TP53 MAPK8IP1 LINC01191 INSM1 GP5 CDKN2A
10 anus cancer 29.4 UBE3A TP53 LINC01191 KRT7 GP5 CDKN2A
11 papilloma 29.4 UBE3A TP53 KRT7 ESR1 CDKN2A
12 adenosquamous carcinoma 29.3 TP53 PGR KRT7
13 adenosarcoma 29.2 TP53 PGR ESR1
14 leiomyosarcoma 29.2 TP53 PGR ESR1 CDKN2A
15 mammary paget's disease 29.2 PGR KRT7 ESR1
16 vagina leiomyosarcoma 29.1 PGR ESR1 CALD1
17 in situ carcinoma 29.1 TP53 PRDX2 PGR ESR1 CDKN2A
18 endometrial hyperplasia 28.7 TP53 PGR HOXA10 ESR1
19 myoma 28.6 PGR HOXA10 ESR1 CALD1
20 clear cell adenocarcinoma 28.5 TP53 PGR KRT7 HOXA10 ESR1
21 endometrial cancer 28.3 TP53 PGR KRT7 HOXA10 ESR1 CDKN2A
22 vaginal carcinosarcoma 11.2
23 vaginal glandular tumor 11.1
24 vaginal squamous tumor 11.1
25 vaginal yolk sac tumor 11.1
26 vaginal endometrial stromal tumor 11.1
27 radiation cystitis 10.5 MAPK8IP2 MAPK8IP1
28 ameloblastic carcinoma 10.5 MAPK8IP2 CDKN2A
29 bartholin's gland carcinoma 10.5 SLC10A2 KRT7
30 vulval paget's disease 10.5 LINC01191 KRT7
31 esophagus verrucous carcinoma 10.5 TP53 CDKN2A
32 lymphocele 10.5 MAPK8IP2 MAPK8IP1
33 cervical basaloid squamous cell carcinoma 10.5 KRT7 CDKN2A
34 spitz nevus 10.5 TP53 CDKN2A
35 vulva adenocarcinoma 10.5 LINC01191 KRT7
36 cervix small cell carcinoma 10.5 MAPK8IP2 MAPK8IP1
37 malignant spiradenoma 10.5 TP53 KRT7
38 inverted transitional papilloma 10.5 KRT7 CDKN2A
39 endometrial transitional cell carcinoma 10.5 KRT7 CDKN2A
40 pancreatic foamy gland adenocarcinoma 10.5 TP53 KRT7
41 anal canal paget's disease 10.5 KRT7 CDKN2A
42 anus basaloid carcinoma 10.4 KRT7 CDKN2A
43 cervical adenoid cystic carcinoma 10.4 KRT7 CDKN2A
44 ovarian melanoma 10.4 MAPK8IP1 CALD1
45 glomangiosarcoma 10.4 TP53 CALD1
46 vaginal tubulovillous adenoma 10.4 KRT7 CDKN2A
47 intratubular embryonal carcinoma 10.4 TP53 KRT7
48 vaginal adenoma 10.4 KRT7 CDKN2A
49 mediastinum sarcoma 10.4 KRT7 CDKN2A
50 necrotizing sialometaplasia 10.4 TP53 KRT7

Comorbidity relations with Vaginal Cancer via Phenotypic Disease Network (PDN):

Acute Cystitis Cervical Cancer
Deficiency Anemia Vulva Cancer

Graphical network of the top 20 diseases related to Vaginal Cancer:

Diseases related to Vaginal Cancer

Symptoms & Phenotypes for Vaginal Cancer

UMLS symptoms related to Vaginal Cancer:

pelvic pain, vaginal pruritus

MGI Mouse Phenotypes related to Vaginal Cancer:

# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.81 CDKN2A ESR1 HOXA10 INSM1 MAPK8IP1 MAPK8IP2
2 homeostasis/metabolism MP:0005376 9.8 CDKN2A ESR1 GP5 HLA-G INSM1 KRT7
3 no phenotypic analysis MP:0003012 9.17 CDKN2A ESR1 INSM1 MAPK8IP2 PGR TP53

Drugs & Therapeutics for Vaginal Cancer

Drugs for Vaginal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 122)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Ondansetron Approved Phase 3 99614-02-5 4595
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
7 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
8 Dermatologic Agents Phase 3
9 Anti-Anxiety Agents Phase 3
10 Antipsychotic Agents Phase 3
11 Gastrointestinal Agents Phase 3
12 Antipruritics Phase 3
13 Autonomic Agents Phase 3
14 Serotonin Agents Phase 3
15 Central Nervous System Depressants Phase 3
16 Serotonin Antagonists Phase 3
17 Emetics Phase 3
18 Antiemetics Phase 3
19 Liver Extracts Phase 3
20 Cola Phase 3
21 Antineoplastic Agents, Hormonal Phase 3
22 Adjuvants, Immunologic Phase 3
23 Narcotics Phase 3
24 Anesthetics Phase 3
25 Anesthetics, General Phase 3
26 Analgesics, Opioid Phase 3
27 Adjuvants, Anesthesia Phase 3
28 Anesthetics, Intravenous Phase 3
29 Analgesics Phase 3
30 DHEA (Dehydroepiandrosterone) Phase 3
31 Immunologic Factors Phase 3
32 Vaccines Phase 3
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
Indinavir Approved Phase 2 150378-17-9 5362440
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
Mycophenolic acid Approved Phase 2 24280-93-1 446541
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
Fondaparinux Approved, Investigational Phase 2 104993-28-4
Bevacizumab Approved, Investigational Phase 2 216974-75-3
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
Aldesleukin Approved Phase 1, Phase 2 110942-02-4, 85898-30-2
Vidarabine Approved, Investigational Phase 2 24356-66-9 32326 21704
Durvalumab Approved, Investigational Phase 2 1428935-60-7
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
Bupropion Approved Phase 2 34911-55-2, 34841-39-9 444
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838

Interventional clinical trials:

(show top 50) (show all 107)
# Name Status NCT ID Phase Drugs
1 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
2 A Randomized Phase III Trial for Evaluation of Usefulness of Pelvic Drains After Radical Hysterectomy and Node Dissection (RHND) Completed NCT00003267 Phase 3
3 Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation Completed NCT01536392 Phase 3 Granisetron;Ondansetron
4 An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL®9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27- to 45-Year-Olds) Compared to Young Adult Women (16 to 26 Year Olds) Completed NCT03158220 Phase 3
5 A Phase III Open-label Safety and Immunogenicity Study of GARDASIL™9 Administered to 9- to 26-Year-Old Females and Males in Vietnam Completed NCT03546842 Phase 3
6 A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women Completed NCT00092521 Phase 3
7 A Phase III, Randomized, International, Placebo-Controlled, Double-Blind Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given to Females 12-26 Years of Age Who Have Previously Received GARDASIL™ Completed NCT01047345 Phase 3
8 Evaluation of Safety and Immunogenicity of GARDASIL™ in Healthy Females Between 9 and 26 Years of Age in SubSaharan Africa Completed NCT01245764 Phase 3
9 A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26- Year-Old Women Completed NCT00543543 Phase 3
10 Phase III Double-Blind Study Of Depot Octreotide Versus Placebo In The Prevention Of Acute Diarrhea In Patients Receiving Pelvic Radiation Therapy Completed NCT00033605 Phase 3 octreotide acetate
11 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
12 Vaginal DHEA for Vaginal Symptoms: A Phase III Randomized, Double Blind, Placebo- Controlled Trial Completed NCT01376349 Phase 3 prasterone
13 A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer Recruiting NCT02466971 Phase 3 Cisplatin;Triapine
14 A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (9 to 15 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds) Active, not recruiting NCT00943722 Phase 3
15 Systematic Nutritional Care in Patients Receiving First-line Chemotherapy for Metastatic Gynecologic Cancer in a Phase II Study Unknown status NCT00905658 Phase 2
16 A Phase I/II Feasibility/Efficacy Study of HIFU in Otherwise Untreatable Pelvic Rectal Cancer Unknown status NCT01097239 Phase 1, Phase 2
17 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
18 Phase II Pilot Trial of Non-Myeloablative Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation Using Fludarabine, Low Dose TBI and Post-Transplant Cyclosporine and Mycophenolate Mofetil Followed by Donor Lymphocyte Infusion for Therapy of Advanced or Metastatic Human Papilloma Virus (HPV) - Associated Cervical Carcinoma Refractory to Standard Therapy Completed NCT00005941 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
20 A Pilot Study of Conformal Intensity Modulated Radiation Therapy (IMRT) for Gynaecological Cancer Patients Not Suitable for Intracavitary Brachytherapy Boost (GY03.2) Completed NCT00188578 Phase 1, Phase 2
21 Women's Cancer Center Protocol #45: Prolonged Venous Thromboembolism Prophylaxis With Fondaparinux in Gynecologic Oncology Patients: An Open Label Phase II Trial Completed NCT00381888 Phase 2 fondaparinux sodium
22 A Phase 2 Study of Triapine® (NSC #663249) and Cisplatin in Combination With Pelvic Radiation for Treatment of Stage IB2-IVa Cervical Cancer or Stage II-IV Vaginal Cancer Completed NCT00941070 Phase 2 triapine;cisplatin
23 A Pilot Study Evaluating The Safety Of Avastin And Pelvic Radiation In Women With Pelvic-Confined Recurrence of Gynecological Cancers Completed NCT00545792 Phase 2 Avastin
24 A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers Completed NCT02280811 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
25 A Randomized, Double-Blinded, Tolerability and Immunogenicity Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered Concomitantly With GARDASIL to 16- to 26- Year-Old Women Completed NCT00551187 Phase 2
26 A Phase IIa Randomized, Double-Blind Controlled With Gardasil, Clinical Trial to Study theTolerability and Immunogenicity of V505 (a Multivalent Human Papilloma Virus [HPV] L1 Virus Like Particle [VLP] Vaccine) in Healthy 16 to 26 Year Old Women Completed NCT00520598 Phase 2 Comparator: V505 formulation 2;Comparator: V505 formulation 2
27 A Prospective Evaluation of a Palliative Radio-Surgical Approach for the Treatment of Gynecologic Malignancies Completed NCT01079832 Phase 2
28 Psychosexual Intervention for Gynecologic and Breast Cancer Patients Completed NCT01764802 Phase 2
29 Effectiveness of an Individualized Symptom Education Program (ISEP) on the Symptom Distress of Women Receiving Radiation for Gynecological Cancer. Completed NCT00275353 Phase 2
30 A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers Completed NCT01585428 Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
31 The LATENT Trial: Lytic Activation To Enhance Neoantigen-directed Therapy A Study to Evaluate the Feasibility and Efficacy of the Combined Use of Avelumab With Valproic Acid for the Treatment of Virus-associated Cancer Recruiting NCT03357757 Phase 2 Valproic Acid
32 Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer Recruiting NCT03180294 Phase 2 Bupropion Hydrochloride
33 A Phase 2, Open-Label Study to Evaluate Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic Human Papilloma Virus Associated Cancers Recruiting NCT03439085 Phase 2
34 A Clinical Trial to Evaluate Image-Guided Gynecologic Brachytherapy in the Advanced Multimodality Image-Guided Operating Suite (AMIGO) Active, not recruiting NCT01399658 Phase 2
35 A Phase I/II Study of HB-201 Monotherapy or in Combination With Checkpoint Inhibitors in Patients With Human Papillomavirus 16 Positive (HPV 16+) Confirmed Cancers' Not yet recruiting NCT04180215 Phase 1, Phase 2 HB-201 intravenous administration;HB-201 intratumoral administration on first cycle, followed by HB-201 intravenous administration on subsequent cycles
36 A Phase II Study of VELCADE TM(PS-341) and Irinotecan in the Treatment of Progressive, Recurrent or Metastatic Cervical, Vulvar, or Vaginal Cancer Terminated NCT00106262 Phase 2 Velcade (bortezomib);Irinotecan
37 A Randomized Phase II Trial of Adjuvant Nivolumab or Expectant Observation Following Neoadjuvant Ipilimumab Plus Nivolumab and Surgical Resection of High-Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma Withdrawn NCT03220009 Phase 2
38 A Phase I Clinical Trial of Intrapleural Adenoviral-Mediated Interferon-beta (IFN-ß) Gene Transfer for Pleural Malignancies Unknown status NCT00066404 Phase 1
39 A Phase I Study of Weekly Oral Topotecan in Gynecologic Malignancies Completed NCT00842452 Phase 1 topotecan hydrochloride
40 Phase I Study of Concomitant Chemoradiotherapy With Vinorelbine and Paclitaxel in Patients With Advanced Pelvic Malignancies Completed NCT00002949 Phase 1 paclitaxel;vinorelbine tartrate
41 Phase I Study of Metronomic Daily Dosing of Docetaxel in Women With Progressive or Recurrent Gynecologic Cancer Completed NCT00287885 Phase 1 docetaxel
42 A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies Completed NCT00523432 Phase 1 Topotecan;CCI-779 (temsirolimus)
43 Phase I Study of Intraperitoneal Administration of 9-Amino-20(S)-Camptothecin to Patients With Cancer Predominantly Confined to the Peritoneal Cavity Completed NCT00003548 Phase 1 aminocamptothecin colloidal dispersion
44 Phase I Study of T Cells Modified With Chimeric AntiCEA Immunoglobulin-T Cell Receptors (IgTCR) in Adenocarcinoma Completed NCT00004178 Phase 1
45 A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
46 An Open Label, Sequential Cohort Dose-Escalation Safety, Tolerability and Pharmacokinetic Study of VEGF Trap Administered Intravenously in Patients With Advanced Solid Tumors or Lymphoma Completed NCT00083213 Phase 1
47 An Open-Label, Long-Term, Safety and Tolerability Study of VEGF Trap Administered Intravenously in Patients With Advanced Solid Tumors or Lymphoma Completed NCT00082823 Phase 1
48 A Randomized, Double-Blind, Multicenter, Biphasic, Controlled With GARDASIL™ Dose-Escalation Study of Octavalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With Amorphous Aluminum Hydroxyphosphate Sulfate (AAHS) and ISCOMATRIX™ (IMX) Completed NCT00851643 Phase 1
49 Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis Completed NCT00003704 Phase 1 capecitabine
50 A Phase I, Pharmacokinetic, and Biologic Correlative Study of R115777 (NSC 702818) and Herceptin in Patients With Advanced Cancer Completed NCT00005842 Phase 1 tipifarnib

Search NIH Clinical Center for Vaginal Cancer

Cochrane evidence based reviews: vaginal neoplasms

Genetic Tests for Vaginal Cancer

Anatomical Context for Vaginal Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Vaginal Cancer:


MalaCards organs/tissues related to Vaginal Cancer:

Breast, Cervix, Testes, Uterus, T Cells, Bone, Liver

Publications for Vaginal Cancer

Articles related to Vaginal Cancer:

(show top 50) (show all 562)
# Title Authors PMID Year
Robotic type II B posterior exenteration for recurrent vaginal cancer. 61 42
31345607 2019
Radiation therapy for vaginal cancer in complete uterine prolapse with intrauterine adhesion: a case report. 61 42
31122220 2019
Gastrointestinal Stromal Tumors Presenting as Vaginal Bleeding. 42
31638548 2019
Photodynamic Therapy for Photodamage, Actinic Keratosis, and Acne in the Cosmetic Practice. 61
31779937 2020
Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of the literature. 61
31959338 2020
Vulvar and vaginal neoplasia in women with inflammatory bowel disease. 61
31718933 2020
Vaginal Intraepithelial Neoplasia: A Retrospective Study of Treatment and Outcomes Among a Cohort of UK Women. 61
31860574 2020
Hyaluronic acid gel injection in rectovaginal septum reduced incidence of rectal bleeding in brachytherapy for gynecological malignancies. 61
31879238 2019
Recommendations from gynaecological (GYN) GEC-ESTRO working group - ACROP: Target concept for image guided adaptive brachytherapy in primary vaginal cancer. 61
31874348 2019
Nail squamous cell carcinoma: A hidden high-risk human papillomavirus reservoir for sexually transmitted infections. 61
30930083 2019
The risk of vaginal cancer is associated with a history of cervical neoplasia. 61
31863542 2019
Prognostic Significance of P16 Expression and P53 Expression in Primary Vaginal Cancer. 61
31593028 2019
Prophylactic vaccination against human papillomaviruses to prevent vulval and vaginal cancer and their precursors. 61
31718338 2019
Anterior Pelvic Exenteration for Chemo-irradiated Non-diethylstilbestrol Exposed Clear Cell Vaginal Cancer. 61
31662571 2019
Sentinel Node Mapping in Gynecologic Cancers: A Comprehensive Review. 61
31630736 2019
Pelvic Exenteration for Locally Advanced and Relapsed Pelvic Malignancies - An Analysis of 100 Cases. 61
31662557 2019
Risk of vaginal cancer among hysterectomised women with cervical intraepithelial neoplasia: a population-based national cohort study. 61
31769577 2019
Neovaginoplasty for radiation-induced vaginal stenosis using Nile Tilapia Fish Skin as a biological graft. 61
31768241 2019
Diagnosis, Therapy and Follow-up of Vaginal Cancer and Its Precursors. Guideline of the DGGG and the DKG (S2k-Level, AWMF Registry No. 032/042, October 2018). 61
31680701 2019
Primary vaginal adenocarcinoma of intestinal-type: case report of a rare gynaecological tumour. 61
31772753 2019
Total Colpectomy Increases the Risk of Postoperative Hydronephrosis in Vaginal Cancer Patients. 61
29469636 2019
Use of multifunctional composite nanofibers for photothermalchemotherapy to treat cervical cancer in mice. 61
31290862 2019
Familial Clustering, Second Primary Cancers and Causes of Death in Penile, Vulvar and Vaginal Cancers. 61
31413311 2019
Human papillomavirus and p16 in squamous cell carcinoma and intraepithelial neoplasia of the vagina. 61
30561092 2019
A Systematic Assessment of Google Search Queries and Readability of Online Gynecologic Oncology Patient Education Materials. 61
29353371 2019
Performance and outcome of pelvic exenteration for gynecologic malignancies: A population-based study. 61
30792003 2019
The healthcare costs of treating human papillomavirus-related cancers in Norway. 61
31064346 2019
Cervical, Vaginal, and Vulvar Cancer Costs Incurred by the Medicaid Program in Publicly Insured Patients in Texas. 61
30907776 2019
Development and assessment of 3D-printed individual applicators in gynecological MRI-guided brachytherapy. 61
31139221 2019
Human Papillomavirus (HPV)-associated Lymphoepithelioma-like Carcinoma of the Vagina and Anal Canal: A Rare Variant of Squamous Cell Carcinoma. 61
29257037 2019
[TNM classification of gynecologic malignancies : What remains to be done beyond 2017?] 61
30707273 2019
Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates. 61
30674687 2019
Patterns and trends of HPV-related cancers other than cervix in South Africa from 1994-2013. 61
30557819 2019
Laterally extended endopelvic resection with nephrectomy for vaginal cancer. 61
30454878 2019
Importance of Colposcopy Impression in the Early Diagnosis of Posthysterectomy Vaginal Cancer. 61
30418351 2019
Severe Vaginal Bleeding in a Case of Renal Cell Carcinoma. 61
31360564 2019
Definitive Radiotherapy in Invasive Vaginal Carcinoma: A Systematic Review. 61
30139838 2019
Gabapentin and Cancer Risk: Updated Findings from Kaiser Permanente Northern California. 61
30939265 2019
Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis. 61
30482913 2019
Vaginal Dysplasia and HIV: An African American and Caribbean American Cohort Study. 61
30693024 2019
Prognostic Significance of P16 Expression and P53 Expression in Primary Vaginal Cancer. 61
30516621 2018
Breast and reproductive cancers in the transgender population: a systematic review. 61
29706033 2018
Inversely designed, 3D-printed personalized template-guided interstitial brachytherapy for vaginal tumors. 61
30479625 2018
Cancer of the vagina. 61
30306589 2018
Incidences and risk factors of metachronous vulvar, vaginal, and anal cancers after cervical cancer diagnosis. 61
30054103 2018
A Clinical Evaluation of American Brachytherapy Society Consensus Guideline for Bulky Vaginal Mass in Gynecological Cancer. 61
30044320 2018
The role of FDG-PET/CT in gynecologic imaging: an updated guide to interpretation and challenges. 61
29520427 2018
KLK5, a novel potential suppressor of vaginal carcinogenesis. 61
29561728 2018
Image-based multichannel vaginal cylinder brachytherapy for the definitive treatment of gynecologic malignancies in the vagina. 61
29929925 2018
Perineural Spread Along Spinal and Obturator Nerves in Primary Vaginal Carcinoma: A Case Report. 61
29660549 2018

Variations for Vaginal Cancer

Cosmic variations for Vaginal Cancer:

9 (show top 50) (show all 940)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88453086 STAT3 vagina,NS,carcinoma,squamous cell carcinoma c.1110-2A>G p.? 17:42329778-42329778 24
2 COSM97074901 PTPRT vagina,NS,carcinoma,squamous cell carcinoma c.3409G>A p.E1137K 20:42106824-42106824 24
3 COSM109089776 NSD1 vagina,NS,carcinoma,squamous cell carcinoma c.5717G>T p.G1906V 5:177280659-177280659 24
4 COSM86305871 NFKBIA vagina,NS,carcinoma,squamous cell carcinoma c.127G>C p.E43Q 14:35404518-35404518 24
5 COSM102126713 EIF1AX vagina,NS,carcinoma,squamous cell carcinoma c.415G>T p.E139* 23:20130530-20130530 24
6 COSM102126718 EIF1AX vagina,NS,carcinoma,squamous cell carcinoma c.64G>C p.E22Q 23:20138575-20138575 24
7 COSM92091529 AURKA vagina,NS,carcinoma,squamous cell carcinoma c.127C>T p.Q43* 20:56386449-56386449 24
8 COSM97571573 ATRX vagina,NS,carcinoma,squamous cell carcinoma c.4498G>A p.E1500K 23:77652173-77652173 24
9 COSM139294266 vagina,NS,carcinoma,squamous cell carcinoma c.1110-2A>G p.? 17:42329778-42329778 24
10 COSM88614470 vagina,NS,carcinoma,squamous cell carcinoma c.127C>T p.Q43* 20:56386449-56386449 24
11 COSM101446479 vagina,NS,carcinoma,squamous cell carcinoma c.127C>T p.Q43* 20:56386449-56386449 24
12 COSM92613846 vagina,NS,carcinoma,squamous cell carcinoma c.4910G>T p.G1637V 5:177280659-177280659 24
13 COSM142601992 vagina,NS,carcinoma,squamous cell carcinoma c.2256G>A p.E753K 20:42106824-42106824 24
14 COSM100346016 vagina,NS,carcinoma,squamous cell carcinoma c.4384G>A p.E1462K 23:77652173-77652173 24
15 COSM94832378 vagina,NS,carcinoma,squamous cell carcinoma c.127C>T p.Q43* 20:56386449-56386449 24
16 COSM144161135 vagina,NS,carcinoma,squamous cell carcinoma c.2206G>A p.E736K 20:42106824-42106824 24
17 COSM103491068 vagina,NS,carcinoma,squamous cell carcinoma c.1110-2A>G p.? 17:42329778-42329778 24
18 COSM101464008 vagina,NS,carcinoma,squamous cell carcinoma c.127C>T p.Q43* 20:56386449-56386449 24
19 COSM96630253 vagina,NS,carcinoma,squamous cell carcinoma c.3382G>A p.E1128K 20:42106824-42106824 24
20 COSM96848041 vagina,NS,carcinoma,squamous cell carcinoma c.3349G>A p.E1117K 20:42106824-42106824 24
21 COSM101457530 vagina,NS,carcinoma,squamous cell carcinoma c.127C>T p.Q43* 20:56386449-56386449 24
22 COSM99883612 vagina,NS,carcinoma,squamous cell carcinoma c.816-2A>G p.? 17:42329778-42329778 24
23 COSM97172725 vagina,NS,carcinoma,squamous cell carcinoma c.3322G>A p.E1108K 20:42106824-42106824 24
24 COSM102100255 vagina,NS,carcinoma,squamous cell carcinoma c.331G>T p.E111* 23:20130530-20130530 24
25 COSM101451548 vagina,NS,carcinoma,squamous cell carcinoma c.127C>T p.Q43* 20:56386449-56386449 24
26 COSM102100262 vagina,NS,carcinoma,squamous cell carcinoma c.17-2734G>C p.? 23:20138575-20138575 24
27 COSM96960471 vagina,NS,carcinoma,squamous cell carcinoma c.3418G>A p.E1140K 20:42106824-42106824 24
28 COSM101460995 vagina,NS,carcinoma,squamous cell carcinoma c.127C>T p.Q43* 20:56386449-56386449 24
29 COSM93285904 vagina,NS,carcinoma,squamous cell carcinoma c.3379G>A p.E1127K 20:42106824-42106824 24
30 COSM140296740 vagina,NS,carcinoma,squamous cell carcinoma c.1110-2A>G p.? 17:42329778-42329778 24
31 COSM96733209 vagina,NS,carcinoma,squamous cell carcinoma c.3352G>A p.E1118K 20:42106824-42106824 24
32 COSM133974130 vagina,NS,carcinoma,squamous cell carcinoma c.127G>C p.E43Q 14:35404518-35404518 24
33 COSM92689842 vagina,NS,carcinoma,squamous cell carcinoma c.4910G>T p.G1637V 5:177280659-177280659 24
34 COSM87033167 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4975C>G p.L1659V 16:2086857-2086857 3
35 COSM88036027 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.775G>C p.D259H 17:7674188-7674188 3
36 COSM87898444 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.536A>G p.H179R 17:7675076-7675076 3
37 COSM87961314 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.719G>T p.S240I 17:7674244-7674244 3
38 COSM87912602 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.550G>A p.D184N 17:7675062-7675062 3
39 COSM88310290 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.868C>A p.R290S 17:7673752-7673752 3
40 COSM87899497 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.586C>T p.R196* 17:7674945-7674945 3
41 COSM87898723 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.817C>T p.R273C 17:7673803-7673803 3
42 COSM88057483 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.875A>G p.K292R 17:7673745-7673745 3
43 COSM87900273 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.427G>A p.V143M 17:7675185-7675185 3
44 COSM87898351 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 3
45 COSM87936758 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.301A>T p.K101* 17:7676068-7676068 3
46 COSM87897745 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.524G>A p.R175H 17:7675088-7675088 3
47 COSM87918718 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.848G>A p.R283H 17:7673772-7673772 3
48 COSM87897839 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.701A>G p.Y234C 17:7674262-7674262 3
49 COSM88192257 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.806G>C p.S269T 17:7673814-7673814 3
50 COSM87915380 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.830G>T p.C277F 17:7673790-7673790 3

Expression for Vaginal Cancer

Search GEO for disease gene expression data for Vaginal Cancer.

Pathways for Vaginal Cancer

Pathways related to Vaginal Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.23 UBE3A TP53 HLA-G CDKN2A

GO Terms for Vaginal Cancer

Biological processes related to Vaginal Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 replicative senescence GO:0090399 9.26 TP53 CDKN2A
2 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.16 TP53 ESR1
3 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 8.96 TP53 ESR1
4 progesterone receptor signaling pathway GO:0050847 8.62 UBE3A PGR

Molecular functions related to Vaginal Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.55 TP53 PGR INSM1 HOXA10 ESR1
2 histone deacetylase binding GO:0042826 9.43 TP53 INSM1 HOXA10
3 protein kinase binding GO:0019901 9.35 TP53 MAPK8IP2 MAPK8IP1 ESR1 CDKN2A
4 MAP-kinase scaffold activity GO:0005078 8.62 MAPK8IP2 MAPK8IP1

Sources for Vaginal Cancer

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....